Další formáty:
BibTeX
LaTeX
RIS
@article{1183203,
author = {Salaj, Peter and Kubes, Radovan and Cetkovský, Petr and Capova, Irena and Penka, Miroslav and Ovesná, Petra and Mesterton, Johan and Lindgren, Peter},
article_location = {Oxford},
article_number = {2},
doi = {http://dx.doi.org/10.1016/j.thromres.2013.11.002},
keywords = {Haemophilia; NovoSeven (R); rFVIIa; High dose; Costs; Time to treatment},
language = {eng},
issn = {0049-3848},
journal = {Thrombosis Research},
title = {Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry},
volume = {133},
year = {2014}
}
TY - JOUR
ID - 1183203
AU - Salaj, Peter - Kubes, Radovan - Cetkovský, Petr - Capova, Irena - Penka, Miroslav - Ovesná, Petra - Mesterton, Johan - Lindgren, Peter
PY - 2014
TI - Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry
JF - Thrombosis Research
VL - 133
IS - 2
SP - 162-167
EP - 162-167
PB - Pergamon-Elsevier Science
SN - 00493848
KW - Haemophilia
KW - NovoSeven (R)
KW - rFVIIa
KW - High dose
KW - Costs
KW - Time to treatment
N2 - Introduction: In the treatment of bleeds in haemophilia patients with inhibitors, a high initial dose of recombinant Factor VIIa (rFVIIa) provides at least equal efficacy and a similar safety profile to a standard initial dose. However, no pharmacoeconomic comparison between these dosing regimens has previously been performed. Here, we assess the pharmacoeconomics of high (> 120 mu g/kg) versus standard (<= 120 mu g/kg) initial rFVIIa dose in inhibitor patients and the impact of time to treatment initiation on costs and outcomes. Methods: In a retrospective analysis, observational data on bleed characteristics, rFVIIa treatment, hospitalizations and outcomes were extracted from the Czech Republic HemoRec registry. Crude comparisons and generalized linear regression modelling (GLM; correcting for patient differences) were performed to compare costs and outcomes between the high and standard initial dosing groups. Results: Of 314 rFVIIa-treated bleeding episodes (12 inhibitor patients), most were spontaneous joint bleeds and 67.5% were treated with a high initial dose. In the crude comparison, high initial rFVIIa dosing was associated with a lower mean number of doses needed to achieve haemostasis compared with standard dosing (p < 0.001), but higher total dose and costs (p <= 0.008). However, regression analyses revealed that high initial dose was associated with similar costs (p = 0.891) and a shorter time to bleeding resolution (p = 0.014). Increasing time to treatment initiation increased both time to bleeding resolution and total costs. Conclusion: Compared with a standard dose, a high initial rFVIIa dose may improve treatment outcomes without increasing costs. Early treatment initiation may reduce treatment costs.
ER -
SALAJ, Peter, Radovan KUBES, Petr CETKOVSKÝ, Irena CAPOVA, Miroslav PENKA, Petra OVESNÁ, Johan MESTERTON a Peter LINDGREN. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry. \textit{Thrombosis Research}. Oxford: Pergamon-Elsevier Science, 2014, roč.~133, č.~2, s.~162-167. ISSN~0049-3848. Dostupné z: https://dx.doi.org/10.1016/j.thromres.2013.11.002.
|
